Titan Pharmaceuticals, Inc. (TTNP)
NASDAQ: TTNP · Real-Time Price · USD
4.450
-0.200 (-4.30%)
Jun 9, 2025, 4:00 PM - Market closed
Company Description
Titan Pharmaceuticals, Inc. does not have significant operations.
Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.
Titan Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1991 |
| IPO Date | Jan 18, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Weei Chay |
Contact Details
Address: 10 East 53rd St., Suite 3001 New York, New York 10022 United States | |
| Phone | 650 244 4990 |
| Website | titanpharm.com |
Stock Details
| Ticker Symbol | TTNP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000910267 |
| CUSIP Number | 888314606 |
| ISIN Number | US8883147055 |
| Employer ID | 94-3171940 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Weei Jye Chay | Chief Executive Officer |
| Brynner Chiam | Acting Principal Financial Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 3, 2025 | 425 | Filing |
| Jun 3, 2025 | 8-K | Current Report |
| Jun 2, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 2, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 2, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 22, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K | Annual Report |